The Down Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Down Syndrome. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Down Syndrome and features dormant and discontinued products.

GlobalData tracks 25 drugs in development for Down Syndrome by 25 companies/universities/institutes. The top development phase for Down Syndrome is preclinical with 14 drugs in that stage. The Down Syndrome pipeline has 21 drugs in development by companies and four by universities/ institutes. Some of the companies in the Down Syndrome pipeline products market are: Eisai, AC Immune and Les Laboratoires Servier.

The key targets in the Down Syndrome pipeline products market include Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1), Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP), and Solute Carrier Family 12 Member 2 (Basolateral Na-K-Cl Symporter or Bumetanide Sensitive Sodium (Potassium) Chloride Cotransporter 1 or SLC12A2 or NKCC1).

The key mechanisms of action in the Down Syndrome pipeline product include Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Inhibitor with seven drugs in Preclinical. The Down Syndrome pipeline products include six routes of administration with the top ROA being Oral and six key molecule types in the Down Syndrome pipeline products market including Small Molecule, and Vaccine.

Down Syndrome overview

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays, and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes unusual for the child’s ethnic group, and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers, and excessive flexibility.

For a complete picture of Down Syndrome’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.